Versant Capital Management Inc Purchases 1,441 Shares of Kenvue Inc. (NYSE:KVUE)

Versant Capital Management Inc increased its position in shares of Kenvue Inc. (NYSE:KVUE) by 300.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,920 shares of the company’s stock after acquiring an additional 1,441 shares during the quarter. Versant Capital Management Inc’s holdings in Kenvue were worth $41,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. State Street Corp grew its holdings in shares of Kenvue by 16.8% in the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company’s stock valued at $2,942,458,000 after buying an additional 18,283,473 shares during the period. Massachusetts Financial Services Co. MA raised its position in shares of Kenvue by 8.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock worth $2,011,832,000 after purchasing an additional 7,115,374 shares during the period. Holocene Advisors LP lifted its holdings in shares of Kenvue by 75.5% during the 3rd quarter. Holocene Advisors LP now owns 13,886,454 shares of the company’s stock valued at $321,194,000 after purchasing an additional 5,975,392 shares in the last quarter. American Century Companies Inc. increased its stake in Kenvue by 20.7% during the 2nd quarter. American Century Companies Inc. now owns 27,382,644 shares of the company’s stock worth $497,816,000 after purchasing an additional 4,700,697 shares in the last quarter. Finally, M&G PLC raised its holdings in Kenvue by 538.0% during the 3rd quarter. M&G PLC now owns 4,341,172 shares of the company’s stock worth $99,847,000 after buying an additional 3,660,730 shares during the period. Institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of KVUE opened at $21.08 on Tuesday. The company’s 50-day moving average is $22.81 and its 200-day moving average is $21.53. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The firm has a market capitalization of $40.42 billion, a PE ratio of 38.33, a PEG ratio of 2.02 and a beta of 1.46. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. The company had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The business’s revenue was down .4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.31 earnings per share. Equities analysts forecast that Kenvue Inc. will post 1.07 EPS for the current year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th were issued a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.89%. The ex-dividend date was Wednesday, November 13th. Kenvue’s dividend payout ratio is 149.09%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on KVUE shares. Barclays raised shares of Kenvue to a “hold” rating in a research report on Thursday, December 12th. Royal Bank of Canada upgraded Kenvue from a “hold” rating to a “moderate buy” rating in a report on Monday, December 9th. Jefferies Financial Group initiated coverage on Kenvue in a report on Tuesday, September 24th. They set a “buy” rating and a $27.00 price objective for the company. Piper Sandler raised Kenvue from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $21.00 to $26.00 in a research report on Monday. Finally, Bank of America lifted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Kenvue currently has a consensus rating of “Hold” and a consensus target price of $23.09.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.